目的:探讨脱氢表雄酮(DHEA)预治疗在卵巢储备低下妇女的体外受精/卵胞质内单精子注射-胚胎移植(IVF/ICSI-ET)周期治疗中的作用。方法:对173例卵巢储备功能低下进行IVF/ICSI-ET的患者进行随机对照研究。DHEA预治疗组(n=81)患者口服DHEA,连用3个月,对照组为未服用DHEA预治疗者(n=92)。观察患者的一般情况、超促排卵情况及胚胎发育和妊娠结局。结果:患者一般情况、hCG注射日子宫内膜厚度及E2水平、Gn使用量和Gn使用天数组间均无统计学差异(P>0.05)。DHEA组IVF受精率、优质胚胎率及临床妊娠率均高于对照组(P<0.05)。但在胚胎种植率、早期流产率、周期取消率组间差异无统计学意义(P>0.05)。结论:DHEA预治疗可以改善卵巢储备功能低下妇女的IVF结局。 Objective: To investigate the role of dehydroepiandrosterone (DHEA) pretreatment in IVF / ICSI-ET cycles in women with low ovarian reserve (IVF / ESG). Methods: A randomized controlled study of 173 patients with IVF / ICSI-ET with poor ovarian reserve. Patients in the DHEA pretreatment group (n = 81) received oral DHEA orally for 3 months, while those in the control group did not receive DHEA pretreatment (n = 92). Observe the general situation of patients, super-ovulation and embryonic development and pregnancy outcomes. Results: There was no significant difference in the general condition, endometrial thickness on the day of hCG injection, E2 level, Gn usage and days of Gn administration (P> 0.05). IVF fertilization rate, high quality embryo rate and clinical pregnancy rate in DHEA group were higher than those in control group (P <0.05). However, there was no significant difference in embryo implantation rate, early abortion rate, and cycle cancellation rate (P> 0.05). Conclusion: Pretreatment with DHEA can improve IVF outcomes in women with ovarian reserve dysfunction.